rhTPO
Trials 31
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-06-15 | Jiangsu HengRui Medicine Co., Ltd. | Results 2026 EHA｜恒瑞创新药海曲泊帕、立康可泮、泽美妥司他等10余项血液学最新研究成果亮相 hengrui.com ↗
海曲泊帕单药的血小板恢复效果与rhTPO单药相当。 |
| 2026-05-27 | Shenyang Sunshine Pharmaceutical Co., LTD. | Results EHA 2026｜三生制药rhTPO与重组抗CD25人源化单克隆抗体4项研究入选，血小板减少症与造血干细胞移植管理临床数据即将公布 3sbio.com ↗
rhTPO 可有效改善 CAR-T 围治疗期重度血小板减少，半数患者 28 天内血小板恢复，高危评分及低基线血小板与恢复延迟、输血负荷高相关。 |
| 2026-05-27 | Shenyang Sunshine Pharmaceutical Co., LTD. | Results ASCO 2026｜三生制药rhTPO与伊尼妥单抗4项研究入选，多瘤种血小板早期干预及乳腺癌新辅助治疗数据即将公布 3sbio.com ↗
宫颈鳞癌同步放化疗中，rhTPO 早期干预可显著提升血小板最低值、缩短血小板恢复时间、降低 G3-5 级重度血小板减少发生率，保障治疗不间断进行。 |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-15 | Jiangsu HengRui Medicine Co., Ltd. | 2026 EHA｜恒瑞创新药海曲泊帕、立康可泮、泽美妥司他等10余项血液学最新研究成果亮相 hengrui.com ↗ |
| 2026-05-27 | Shenyang Sunshine Pharmaceutical Co., LTD. | EHA 2026｜三生制药rhTPO与重组抗CD25人源化单克隆抗体4项研究入选，血小板减少症与造血干细胞移植管理临床数据即将公布 3sbio.com ↗ |
| 2026-05-27 | Shenyang Sunshine Pharmaceutical Co., LTD. | ASCO 2026｜三生制药rhTPO与伊尼妥单抗4项研究入选，多瘤种血小板早期干预及乳腺癌新辅助治疗数据即将公布 3sbio.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 33 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rh-TPO | “A Randomized Phase II Study of Recombinant Human Thrombopoietin (Rh-TPO) and Recombinant Human Interleukin-11 (rhIL-11) for Recurrent Colorectal Cancer (CRC) Patients With...” NCT03823079 ↗ |
| Known as | recombinant human thrombopoietin | “This is a multicenter, prospective, single-arm, phase II clinical study evaluating the early prophylactic use of recombinant human thrombopoietin (rhTPO) to prevent...” NCT07848672 ↗13“To explore the early intervention timing of recombinant human thrombopoietin (rhTPO) for cancer treatment-induced thrombocytopenia (CTIT) in cervical squamous cell carcinoma...” NCT07649395 ↗ “A Randomized Phase II Study of Recombinant Human Thrombopoietin (Rh-TPO) and Recombinant Human Interleukin-11 (rhIL-11) for Recurrent Colorectal Cancer (CRC) Patients With...” NCT03823079 ↗ “Recombinant human thrombopoietin (rhTPO) is a full-length glycosylated-TPO produced by Chinese hamster ovary cells, which showed its effectiveness in ITP in a variety of studies.” NCT04516837 ↗ “The aim of this study was to determine the safety and efficacy of recombinant human thrombopoietin (rhTPO) for the management of immune thrombocytopenia (ITP) during pregnancy.” PMID 28630121 ↗ Jun 2017 “Recombinant human thrombopoietin (rhTPO) is also a kind of a TPO receptor agonists which is highly specific platelet stimulating factor.” NCT04324060 ↗ “Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited \[SUNSHINE\], Shenyang, China” NCT02707497 ↗ “subcutaneous injection of recombinant human thrombopoietin (rhTPO) 15000U once a week during the radiotherapy.” NCT05944809 ↗ “Recombinant human thrombopoietin (rhTPO), a full-length glycated TPO, is a recombinant form of c-Mpl ligand” NCT03771378 ↗ “Recombinant human thrombopoietin (rhTPO) is approved for thrombocytopenia after solid tumor chemotherapy” NCT04168138 ↗ “recombinant human thrombopoietin (rhTPO) + cyclosporine (CsA)” NCT07653581 ↗ |
| Known as | Recombinant Human TPO | “Recombinant Human TPO” NCT01805648 ↗ |
| Known as | TPIAO | “Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited \[SUNSHINE\], Shenyang, China” NCT02707497 ↗ |
| Known as | TPIAOTM | “Rh-TPO (TPIAOTM, a product of Sunshine Pharmaceutical Co Ltd, China, approved by China State Food and Drug Administration)” NCT01506414 ↗ |
| Action | Activate | “Both rhTPO and eltrombopag act on TPO receptors to increase platelets.” NCT03771378 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Thrombopoietin” NCT00283582 ↗ |
| Route | Intravenous | “intravenous rhTPO” NCT00283582 ↗ |